Author

Hanna Usenko

Institution: City Clinical Hospital

Observed institution: City Clinical Hospital

OpenAlex ID: A5085607673

Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

2022 · Matthew S. Davids, Asher Chanan-Khan, et al. · Blood · 16

Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (R/R CLL/SLL)

2021 · Matthew S. Davids, Tanya Siddiqi, et al. · Blood · 2

P-296 Lighthouse: melflufen, daratumumab, and dexamethasone versus daratumumab in relapsed/refractory multiple myeloma refractory to an imid and a proteasome inhibitor or with ≥3 prior lines of therapy

2023 · Maria-Victoria Mateos, Monika Szarejko, et al. · Clinical Lymphoma Myeloma & Leukemia

Works count: 3

Citation count: 18

H-index: 2

I10-index: 1